Semaglutide is the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent in most markets through 2031, but the Indian patent expired in March 2026 and a wave of generics from Biocon, Dr. Reddy's, and others followed within weeks.
The cardiovascular and renal evidence has expanded fastest. SELECT showed a 20% reduction in MACE for non-diabetic adults with obesity. The REMODEL trial (presented at the World Congress of Nephrology 2026) showed direct kidney protection independent of weight loss. Cell Metabolism work from Sinai Health pinned MASH reversal to liver sinusoidal endothelial cells, not weight loss or appetite. JAMA published a 90,000-patient HFpEF analysis showing a 42% reduction in heart-failure hospitalization or all-cause mortality.
The compounding story keeps moving in parallel. The FDA proposed excluding semaglutide from the 503B bulks list on April 30, 2026, with public comment open through June 29. Tirzepatide and liraglutide were folded into the same proposal.
On September 7, 2026, Novo reported first Phase 3 results in children under 12: the STEP Young trial in 165 children aged 6 to under 12 years with obesity showed 40.4% below the obesity threshold at week 68 on semaglutide (max 1.7 mg or 2.4 mg by baseline weight) plus lifestyle modification, versus 0% on placebo; safety matched adult and adolescent experience, with no signal for growth or pubertal development. Detailed results are due at ObesityWeek 2026 in Washington DC (November 14-17). A supplemental filing to extend the U.S. Wegovy label below the current 12-and-older indication has not been announced.
A University of Michigan simulation published October 7, 2026 in Obesity modeled Black and White adults aged 65 to 70 with a BMI of 35 or higher and cardiovascular disease over 25 years. Compared with no treatment, semaglutide 2.4 mg cost $7,300 and sleeve gastrectomy $12,100 per quality-adjusted life year gained, and surgery cost $53,700 per extra quality-adjusted year compared with semaglutide, within the model's $100,000 threshold. Surgery was the most cost-effective option in 57% of simulations; semaglutide was slightly more equitable between the two groups but not enough to change the ranking.
A Phase 3 trial published October 7, 2026 in Diabetes, Obesity and Metabolism randomized 462 Chinese adults with obesity (BMI of 28 or higher) and no diabetes at 30 centers to once-weekly HD1916, a semaglutide made by chemical synthesis instead of in yeast, or to Novo Nordisk's Wegovy for 44 weeks. Weight fell 13.1% with HD1916 and 14.4% with Wegovy, a 1.35-percentage-point gap that stayed inside the preset equivalence margin of 4.16 points, and 87.8% versus 90.5% lost at least 5% of their body weight. The open-label trial was sponsored by the drug's developer, CSPC Baike (Shandong) Biopharmaceutical, whose employees are among the authors; side effects of any grade occurred in 86.5% and 89.2% of participants, mostly mild to moderate.
At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.
Novo Nordisk reported on Thursday, October 1, 2026, at EASD in Milan, a post hoc, exploratory analysis pooling 1,919 adults from its STEP UP and STEP UP T2D trials who took Wegovy 7.2 mg, Wegovy 2.4 mg, or placebo. In a 55-person subgroup whose liver fat was measured by MRI, average liver fat fell from 8.8% at baseline to 3.1% at week 72, and 23 of the 26 participants who started above the 5% threshold for fatty liver ended below it. Liver fat was not a prespecified endpoint of either trial, and Novo pooled the two Wegovy doses for the MRI result.
Full results of Novo's REMODEL trial, first presented at the 2026 World Congress of Nephrology, were published in Nature Medicine on Thursday, October 1, 2026. The trial randomized 106 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo for 52 weeks to learn how the drug protects the kidneys. Its coprimary MRI measures of kidney oxygenation, perfusion, and inflammation did not change significantly versus placebo, but semaglutide lowered the renal artery resistive index and kept stable an MRI marker the authors link to scarring, and paired biopsies showed marked effects on the cells lining the kidney's filtering blood vessels, with fewer immune cells nearby. Urine albumin fell 40% in an exploratory analysis; Novo Nordisk funded the trial.
A cross-sectional, case-control study presented at the European Academy of Dermatology and Venereology Congress in Vienna (September 30 to October 3, 2026) compared 575 GLP-1 receptor agonist users with 1,329 people with type 2 diabetes, obesity, or both who had never taken the drugs, in France, the U.S., Brazil, and Mexico. Users reported nail detachment far more often (39% vs. 9%), along with nail discoloration (46% vs. 17%) and unusual hair loss (50% vs. 34%); after adjustment, nail detachment and discoloration remained roughly two to three times as frequent. The symptoms were self-reported, about half of users said they had nail problems before treatment, and the design cannot show that the drugs cause these changes; Gizmodo reported that the work was funded by Pierre Fabre.
Two retrospective analyses by Shields Health Solutions and partner health systems, presented at the NASP inSPire2026 specialty pharmacy meeting (September 22-25) and reported by AJMC on September 25, 2026, examined GLP-1 therapy managed by health-system specialty pharmacies. At NYU Langone Health, 115 of 2,943 adults (83.4% commercially insured) who started injectable liraglutide, semaglutide, dulaglutide, or tirzepatide between August 2022 and May 2025 stopped within a year (3.9%), with stopping defined as at least 70 days without medication on hand; rates were 1.8% for tirzepatide, 6.1% for semaglutide, 5.9% for dulaglutide, and 25% for liraglutide. A second analysis of 1,707 patients found a median of five days from prescription to first dispense, prior authorization for 95%, and a median out-of-pocket cost of $24.98; the authors noted the single-organization design and lack of a comparison group.
A post-authorization safety study required by the European Medicines Agency and funded by Novo, presented at EASD by Anton Pottegård of the University of Southern Denmark, compared 97,464 new users of semaglutide for type 2 diabetes in Denmark, Sweden, and Norway with propensity-matched new users of insulin, a sulfonylurea, or an SGLT2 inhibitor. After a one-year lag, there were 131 pancreatic cancers among semaglutide users and 123 among comparators, a pooled hazard ratio of 0.91 (95% CI 0.71 to 1.16). Median follow-up after the lag was 1.4 to 1.85 years, which limits conclusions about longer-term risk.
Novo announced on Tuesday, September 29, 2026 results of COMPETE SWITCH CV, a retrospective analysis of U.S. claims data from Komodo Health (January 2018 to September 2025) in adults with type 2 diabetes who had been taking semaglutide 1 mg. Over up to 720 days, the 185,705 people who escalated to semaglutide 2 mg had a 6% lower adjusted risk of death, heart attack, or stroke than the 23,104 who switched to tirzepatide (adjusted hazard ratio for switching 1.06; 95% CI 1.04 to 1.08). Novo said the analysis shows an association rather than cause and effect, may carry residual confounding, and did not assess safety outcomes.
The FDA issued a warning letter dated September 18, 2026 to Houston-based Empower Pharmacy after a November 3-14, 2025 inspection, saying its compounded semaglutide and tirzepatide products appear to be 'essentially copies' of FDA-approved drugs and did not meet the conditions of section 503A. The agency said prescriber determinations of a 'significant difference' appeared to be repeated verbatim across many records, suggesting they may be pre-generated, and called the differences between Empower's products and the approved drugs 'pretextual.' The letter also cites insanitary conditions, including inadequate smoke studies of airflow in the ISO 5 area and media fills not run under the most challenging conditions. Empower has 15 working days to respond; BioSpace reported the letter on September 24.
An updated systematic review by Areesha Moiz, Mark Eisenberg, and colleagues, published online September 1, 2026 in the Annals of Internal Medicine, covered 38 randomized trials in 25,816 adults with overweight or obesity and without diabetes, adding 14 trials to the authors' earlier review. Among marketed drugs, the highest placebo-subtracted weight loss reported was 5.8% for liraglutide, 14.8% for subcutaneous semaglutide, 14.3% for oral semaglutide, 12.4% for orforglipron, and 19.0% for tirzepatide; emerging agents reached 23.9% with amycretin and 22.1% with retatrutide. Gastrointestinal adverse events occurred in 76.0% of patients on GLP-1 drugs versus 40.1% on placebo, and discontinuation for adverse events was 10.7% versus 3.4%. The authors said heterogeneity prevented a pooled quantitative analysis, so these figures are the highest values from individual trials rather than combined estimates.
A systematic review and meta-analysis of head-to-head comparisons of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy) in adults with overweight or obesity — published in Diabetes, Obesity and Metabolism and covered by Medscape on September 9, 2026 with running weekend commentary — synthesized 10 studies (three randomized controlled trials and seven retrospective cohort studies) enrolling 41,381 adults. Tirzepatide produced a mean 4.28 percentage-point greater percent-body-weight reduction than semaglutide (10 studies) and a mean 4.43 kg greater absolute weight loss (8 studies). One head-to-head study reported average weight loss of 50.3 lbs (22.9 kg) on tirzepatide versus 33.1 lbs on semaglutide. Gastrointestinal adverse events were common in both arms but somewhat more frequent with tirzepatide; serious adverse event rates were rare but higher on tirzepatide than semaglutide. The pooled evidence supports the SURMOUNT-5 head-to-head randomized readout published in the New England Journal of Medicine in 2025 (Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks). The tirzepatide-semaglutide efficacy gap plus the safety trade-off remains a live clinical decision point in a market where 12%+ of U.S. adults are on the GLP-1 class per recent surveys.
Novo Nordisk (NYSE: NVO) announced Monday September 7, 2026 first results from STEP Young, a Phase 3 randomized double-blind placebo-controlled multinational trial evaluating once-weekly semaglutide combined with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. The trial enrolled 165 children, dosed with a maximum of 1.7 mg or 2.4 mg semaglutide based on baseline weight. At week 68, 40.4% of the semaglutide group had a BMI below the obesity threshold versus 0% in the placebo group; more than 85% of enrolled children had class II or III severe obesity (BMI ≥35 or ≥40 by adult equivalents) at baseline. Safety and tolerability were consistent with adult and adolescent trials with no new safety concerns and no signals related to growth or pubertal development. Detailed results will be presented at ObesityWeek 2026 in Washington DC November 14-17. Wegovy is currently approved in the U.S. for adolescents 12 and older; a supplemental submission for children under 12 has not been announced.
Wiley's Diabetes, Obesity and Metabolism published in August 2026 pooled subgroup analyses from Novo Nordisk's Phase 3 SOUL (oral semaglutide 14 mg in type 2 diabetes with ASCVD/CKD) and SELECT (semaglutide 2.4 mg in overweight/obesity with established cardiovascular disease) trials examining whether cardiovascular benefit of semaglutide varies by baseline aspirin use. Analyses (Müller-Wieland et al.) concluded that semaglutide significantly reduces major adverse cardiovascular events irrespective of baseline aspirin therapy in individuals with T2DM or overweight/obesity without diabetes at high cardiovascular risk. The pooled MACE benefit is directionally consistent in aspirin users and non-users. Clinical implication: cardiovascular protection from semaglutide is additive to baseline antiplatelet therapy and does not require aspirin discontinuation, addressing a long-standing question about interaction between the GLP-1 receptor agonist class and standard secondary-prevention regimens in older cardiovascular patients.
H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.
Real-world evidence for Wegovy (semaglutide 2.4 mg once weekly subcutaneous injection) documents 5.9% to 12% mean body weight reduction at 6 to 12 months across registry and claims analyses. This compares to 14.9% weight loss in the STEP-1 registrational trial that supported the FDA approval. The gap is primarily adherence-driven: missed doses, titration pauses, insurance-driven dose changes, and stop-restart cycles flatten real-world curves relative to the tight-adherence STEP-1 population. Cleveland Clinic research confirmed that injectable obesity medications produce smaller weight loss in a real-world setting compared to randomized clinical trials, with the gap larger in patient subgroups facing financial barriers to consistent supply. A large real-world study of nearly 8,000 patients who discontinued GLP-1 therapy found that most manage to keep the weight off or continue losing by restarting treatment, switching medications (typically to tirzepatide or higher-dose Wegovy), or adopting lifestyle changes. Patient satisfaction is driven primarily by perceived effectiveness rather than tolerability: effective weight loss even with gastrointestinal side effects is associated with continued treatment adherence, while lower-efficacy responses lead to early discontinuation regardless of tolerability. The real-world evidence has implications for retatrutide's likely commercial trajectory: the 28.3% TRIUMPH-1 result may translate to 15-20% in real-world use depending on adherence patterns, which is still substantially above semaglutide's real-world 5.9-12% range.
Novo Nordisk released detailed data from the REDEFINE 4 head-to-head 84-week Phase 3 trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) versus tirzepatide 15 mg. Trial design: 809 randomized adults with obesity and one or more comorbidities with mean baseline body weight of 114.2 kg, both drugs administered once weekly subcutaneously over 84 weeks. Primary endpoint results: CagriSema 23.0% weight loss versus tirzepatide 25.5% (treatment-policy estimand); CagriSema 20.2% versus tirzepatide 23.6% (treatment-regimen estimand). The trial missed the primary non-inferiority endpoint on weight loss for CagriSema compared to tirzepatide at 84 weeks. CagriSema safety profile was generally well-tolerated. The trial result complicates the Novo commercial positioning of CagriSema as its tirzepatide-beating differentiated response, though the FDA decision on the CagriSema obesity indication remains expected late 2026 based on the REDEFINE 1 and REDEFINE 2 pivotal trials submitted December 18, 2025. The head-to-head result adds to the widening Lilly-Novo franchise gap: Lilly Q2 2026 Mounjaro + Zepbound reached $14.9 billion in the quarter, while Novo H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion).
The higher-dose Wegovy 7.2 mg (semaglutide 7.2 mg once weekly subcutaneous injection, up from the current 2.4 mg maximum approved dose) is currently under FDA review for the adult obesity indication. The submission is based on the Phase 3 STEP UP trial that documented approximately 19% weight loss at the 7.2 mg dose over 68 weeks, versus approximately 15% weight loss for the currently-approved 2.4 mg dose (based on STEP 1 registrational data). The higher-dose submission provides Novo Nordisk with a line-extension option to defend the Wegovy franchise economics against the Eli Lilly tirzepatide franchise (Zepbound and Mounjaro), which continues to outperform on weight loss (approximately 21% at the 15 mg weekly dose per SURMOUNT-1). The Wegovy 7.2 mg efficacy also lags the Lilly retatrutide triple-agonist Phase 3 TRIUMPH-4 data that documented 28.7% mean body weight reduction at the 12 mg dose (the highest weight-loss magnitude in any Phase 3 obesity trial to date). Novo Nordisk's line-extension strategy is under scrutiny following the CagriSema REDEFINE 4 head-to-head miss versus tirzepatide (23.0% vs 25.5% treatment-policy estimand at 84 weeks). FDA decision timing on Wegovy 7.2 mg has not been publicly disclosed.